ClinicalTrials.gg
RecruitingNCT07132827Updated Nov 17, 2025

Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps

A Phase 3 interventional study of SHR-1905 Injection and SHR-1905 Placebo Injection in Chronic Rhinosinusitis With Nasal Polyps, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies in Nasal Polyps with a site in China — 17 open to participants now, 24 under way, 7 of them phase 3. Nasal Polyps · China.

Planned enrollment
5th of 43
280 · median 90
Started
2025
with 6 others
Phase 3
14 of 46
3 open now
Primary completion
2028-04
later than 20 of 23 live
Registered
34th of 46
by date
Lead sponsor
2 of 46
Guangdong Hengrui Pharmaceutical Co., Ltd

Among the 46 studies in Nasal Polyps with a site in China, this one is the 5th largest by planned enrollment of the 43 interventional ones that give a count, is one of 7 that started in 2025, is one of 14 in phase 3, reaches primary completion later than 20 of the 23 other live ones, and was the 34th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

17 of the 46 studies in Nasal Polyps with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Nasal Polyps with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy, and safety of SHR-1905 injection in subjects with chronic rhinosinusitis with nasal polyps (CRSwNP)

03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Weight ≥40kg
  2. Diagnosed with chronic rhinosinusitis with nasal polyps (CRSwNP).
  3. Bilateral nasal polyps at screening and baseline, total NPS ≥5, ≥2 points for each nostril.
  4. NCS ≥2 at screening and baseline.
  5. SNOT-22≥30 at screening period and baseline.
  6. Recorded persistent NP symptoms for over 4 weeks prior to screening.
  7. Subjects received standard therapy with intranasal (INCS) prior to randomization.
  8. NP surgery in the past and/or SCS use within 1 years before screening(or with / intolerances).

Exclusion criteria

Exclusion Criteria:

  1. Any comorbidities that may affect the efficacy evaluation of nasal polyps.
  2. Any comorbidities except for asthma that may affect blood EOS levels.
  3. Concomitant with immunodeficiency.
  4. Concomitant with or not suitable for nasal endoscopy.
  5. Uncontrolled hypertension and/or uncontrolled diabetes.
  6. Concomitant with infection within 4 weeks prior to randomization.
  7. Uncontrolled epistaxis within 4 weeks prior to randomization.
  8. Major surgery performed within 3 months prior to randomization, or surgery planned during the study, or treatments that may affect evaluations according to investigators.
  9. Parasitic infection within 6 months before randomization.
  10. Sinus or intranasal surgery within 6 months prior to screening, or changes in the nasal walls caused by sinus or intranasal surgery that made NPS evaluation impossible.
  11. diagnosed within 5 years before randomization (except those with a low risk of or death).
  12. Abnormalities of laboratory tests at screening or baseline.
  13. Concomitant with active , positive virus antibodies, positive antibodies, or positive treponema pallidum antibodies.
  14. Prolonged or other abnormal results of at screening or baseline that may cause significant safety risks to subjects.
  15. before the use of bronchodilator (pre-BD) was less than 50% at screening.
  16. Transfusion of blood products or immunoglobulin within 4 weeks prior to randomization.
  17. SCS or additional INCS use within 4 weeks before randomization, or planned use during treatment period.
  18. Regular use of decongestants (local or systemic) within 4 weeks before randomization, except for during the endoscopic procedure.
  19. Adnimistration of or viral vector vaccine within 4 weeks before randomization.
  20. Allergen immunotherapy within 8 weeks before randomization.
  21. Smoking at screening, or smoking cessation less than 6 months at screening.
  22. Substance abuse, drug abuse, and/or excessive alcohol consumption within 1 year prior to randomization.

Pregnancy (including positive pregnancy test at screening or baseline), lactation, or pregnancy plan during study period.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    SHR-1905 Injection

    Drug: SHR-1905 Injection

  • Placebo comparator
    SHR-1905 Placebo Injection

    Drug: SHR-1905 Placebo Injection

Interventions

  • SHR-1905 Injection

  • DrugSHR-1905 Placebo Injection

    SHR-1905 Placebo Injection

06

What researchers measure

Primary outcomes

  1. Nasal polyp scores (NPS)

    Change from baseline in NPS at Week 24.

    Time frame: Baseline to Week 24

  2. Nasal Congestion Scores (NCS)

    from baseline in NPS at Week 24.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Lund Mackay score (LMK) from baseline on sinus CT scan

    Time frame: Baseline to Week 24

  2. Loss of smell

    Time frame: Baseline to Week 24

  3. Proportion of subjects with NPS≤1 point per nostril

    Time frame: Baseline to Week 24

  4. Sino-nasal outcome test-22 (SNOT-22) scores

    Time frame: Baseline to Week 24

  5. Total symptoms score (TSS)

    Time frame: Baseline to Week 24

07

Study locations

1 of 1 sites recruiting
  • Eye & Ent Hospital of Fudan University
    Shanghai, Shanghai Municipality 200031, China
    Recruiting
    • Dehui Wang · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Apr 2028, 32 months after the start.

Of 30 industry-sponsored phase 3 interventional studies under Nasal Polyps, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's planned 32 months is above that.

Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 19 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2025
First posted
Aug 20, 2025
StartActual
Aug 28, 2025
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07132827
Responsible party
Sponsor
First posted
Aug 20, 2025
Start date
Aug 28, 2025
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Nov 17, 2025

Study contacts

HuanHuan Huang
Contact
huanhuan.huang.hh30@hengrui.com
+0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1905

Start the discussion